KIR ligand incompatibility in graft versus host disease is associated with natural killer (NK) cell alloreactivity. 1 The effect of this incompatibility on outcomes of haploidentical or mismatched unrelated hematopoitic stem cell transplantation (HSCT) remains controversial, [1] [2] [3] possibly because of assessments using different transplant protocols with varying levels of T-cell depletion in vitro or in vivo. In recent years, we have successfully established a novel conditioning protocol that includes anti-thymocyte globulin followed by haploidentical HSCT without in vitro T-cell depletion, and we have found that this protocol can achieve outcomes comparable to those obtained with HLA-matched transplantation. 4 Because of inconsistent NK cell-mediated alloreactivity in haploidentical or mismatched unrelated HSCT, we analyzed the relationship of the KIR ligand mismatch with clinical outcomes in our cohort of 116 patients.
This analysis included 116 recipients of haploidentical donor HSCT at the Peking University Institute of Hematology between November 2002 and October 2005; patients had allele-level molecular typing performed at HLA-A, -B, -C and -DRB1. Cases were divided into those with and those without KIR ligand incompatibility, as described by Ruggeri et al. 1 based on known KIR ligands (HLA-C alleles with Asn77-Lys80; HLA-C alleles with Ser77-Asn80; and HLA-Bw4 alleles). All patients and their donors gave written informed consent, and this study was approved by the Institutional Review Board of Peking University Institute of Hematology.
All patients received myeloablative therapy that included a combination of cytosine arabinoside (Ara-C 4 g/m 2 Â 2 days), busulfan (12 mg/kg), cyclophosphamide (1.8 g/m 2 Â 2 days), Simustine (250 mg/kg) and rabbit anti-human thymocyte immunoglobulin (ATG 10 mg/kg, from day 5 to day 2). A combination of granulocyte colony-stimulating factor-primed bone marrow (G-BM) and peripheral blood stem cells (PBSC) without in vitro T-cell depletion was used as a stem cell source in all 116 patients. Prophylaxis of acute graft-versus-host disease (aGVHD) was the same for all patients and consisted of cyclosporin and short-term methotrexate with mycophenolate mofetil. Detailed haploidentical myeloablative regimens have been reported by Huang et al. 4 Pretransplantation risk categories included standard or high risk. Patients with standard risk were defined as those undergoing transplantation during the first complete remission of acute lymphoblastic leukemia/myeloblastic leukemia (ALL/ AML) or the first chronic phase of chronic myelogenous leukemia (CML). Patients with high-risk were those with myelodysplastic syndrome (MDS), adult acute mixed lineage leukemia (AMLL), or a more-advanced stage of ALL/AML or CML beyond first complete remission or first chronic phase. Furthermore, patients were classified into 'low'-or 'high'-T-cell groups, based on whether they received less or more than a median CD3 þ cell dose of 1.48 Â 10 8 /kg in the allograft. Data as of 2 November 2006, were analyzed. Overall survival (OS) was estimated using Kaplan-Meier methods, and the probabilities of relapse, transplant-related mortality (TRM), grades II to IV aGVHD and the probability of both absolute neutrophil count (ANC) and platelet count (PLT) recovery were calculated as cumulative incidence to adjust the analysis for competing risks. Log-rank test statistics were used to evaluate the univariate effects of KIR ligand incompatibility on outcome. To evaluate the independent effect of KIR ligand incompatibility, a Cox regression analysis was performed. Factors included in the models were recipient and donor ages, sex, diagnosis, HLA mismatch, KIR ligand mismatch, pretransplantation risk category, 'high' vs 'low' CD3 þ T-cell group, and dose of CD34 þ cells. The final multivariate models were built using a forward stepwise model selection approach. Patient characteristics between the two groups were compared using w 2 statistics for categorical variables and Mann-Whitney U-test for continuous variables, respectively.
Among the 116 patients, 30 had KIR ligand mismatch (eight patients with AML, 12 patients with ALL, 10 patients with CML) and 86 lacked KIR ligand mismatch (26 patients with AML, 28 patients with ALL, 25 patients with CML and five and two patients with MDS and AMLL, respectively). There were no significant differences in recipient age, diagnosis, pretransplantation risk category, HLA incompatibility or dose of CD3 þ T cells and CD34 þ cells between the two groups (data not shown). The probability of ANC recovery at day 100 was 100% for both groups, with a median recovery times of 12 and 13 days for patients with and without KIR ligand mismatch, respectively. The probabilities of PLT recovery at day 100 were 86.7 and 88% for patients with and without KIR ligand incompatibility, respectively. The median times to PLT recovery in the two groups were 18 and 17 days, respectively (P40.05). No rejections occurred in any of the 116 patients after transplantation.
Multivariate analysis showed that both KIR ligand mismatch (HR 2.484, confidence interval (CI) 1.241-4.973, P ¼ 0.01) and 'high'-dose T-cell categorization (41.48 Â 10 8 /kg) (HR 4.099, CI 1.899-8.849, P ¼ 0.0003) were independent risk factors for aGVHD. There was a higher cumulative incidence of aGVHD in patients with KIR ligand mismatch compared to those patients without KIR ligand mismatch (61.9710.6 vs 34.875.9%, P ¼ 0.013; Figure 1a ), or in patients in the 'high-' T cell group compared to those in the 'low'-T cell group (59.177.4 vs 23.876.6%, P ¼ 0.001). Meanwhile, KIR ligand mismatch significantly increased the incidence of aGVHD in the 'high'-T cell group (9079.5 vs 5078.8%, P ¼ 0.039), but had little effect in the 'low'-T cell group (36.4714.5 vs 21.277.1%, P ¼ 0.213). We found a significant and striking difference in the cumulative incidence of aGVHD between the patients with KIR ligand mismatch in the 'high'-T cell group and those without KIR ligand mismatch in the 'low'-T cell group (Po0.00001; Figure 1b) .
The aGVHD rate did not depend on the degree of HLA compatibility regardless of the presence or absence of KIR ligand mismatch. For those with a one-, two-or three-loci mismatch (according to HLA-A, -B or -DR typing between donor and recipients), the aGVHD rates were, respectively, 71.4, 58.3 and 40% in patients with KIR ligand incompatibility and 21.7, 47.2 and 34.6% in patients without KIR ligand incompatibility (Figure 1c ). For the above three subgroups, KIR ligand mismatch significantly increased the aGVHD rate only in those patients with one locus mismatch (P ¼ 0.029; Figure 1c ). Because the HLA-C molecule has been well defined as the predominant ligand for the inhibitory KIR receptor in NK cells, we further analyzed the effect of KIR ligand mismatch on aGVHD based on HLA-C allele mismatch. In HLA-C allele mismatch group, KIR ligand mismatch worsened the adverse effect of HLA-C allele mismatch on aGVHD (63.2711.1 vs 41.377.3, P ¼ 0.059; Figure 1d ). The KIR ligand mismatch may involve more than one HLA allele mismatch, and synergism among allele mismatches may intensify aGVHD.
Multivariate analysis demonstrated that both high-risk leukemia and KIR ligand mismatch were independent predictors for OS (HR 3.544, CI 1.396-8.995, P ¼ 0.008; and HR 2.230, CI 1.003-4.960, P ¼ 0.049, respectively) and relapse (HR 8.080, CI 1.427-45.75, P ¼ 0.018 and HR 4.771, CI 1.315-17.312, P ¼ 0.017, respectively); high-risk leukemia was the only independent predictor for TRM. No other factors regarding recipient, donor or transplant-related characteristics were found to influence clinical outcomes. Therefore, we analyzed the effect of KIR ligand mismatch on clinical outcomes based on the high-and standard-risk groups. In the standard-risk group, KIR ligand mismatch increased aGVHD incidence (87.5711.7 vs 34.378%, P ¼ 0.001), possibly eliciting a higher TRM (37.5717.1 vs 6.274.3%, P ¼ 0.011; Figure 2a) , and then resulted in poorer patient survival (62.5717.1 vs 90.475.3% at 4 year, P ¼ 0.030; Figure 2c ). The beneficial roles of alloreactive NK cells on the graft versus leukemia effect might have been inhibited by the large dose of T cells in the allograft in our protocol, 5 and relapse was not the key problem in the standard risk group; therefore, there were no effects of KIR ligand mismatch on relapse in standard-risk patients (0 vs 875.4%, P ¼ 0.575; Figure 2b ). In contrast, KIR ligand mismatch further worsened the high-relapse rate in the high-risk group (63.5718.4 vs 12.579%, P ¼ 0.003; Figure 2b ). No significant differences of cumulative probability of aGVHD, TRM and OS from patients with and without KIR ligand mismatch were observed.
When analyzed separately, patients with KIR ligand mismatch had comparable TRM rates compared with their KIR ligandcompatible counterparts (Figure 2d ), but had a higher cumulative relapse rate and inferior OS rate in the AML (n ¼ 34) and ALL (n ¼ 40) groups (relapse: 27.1716.5 vs 0%, P ¼ 0.007 for AML and 53.7717.8 vs 6.776.4%, P ¼ 0.003 for ALL; Figure 2e ) (OS: 50717.7 vs 81.978.3%, P ¼ 0.040 for AML and 35715.4 vs 74.879.0%, P ¼ 0.044 for ALL, Figure 2f , respectively). However, KIR ligand mismatch had little effect on other myeloid disease patients, including those with CML, MDS or AMLL. Characteristics including HLA mismatch, doses of CD3 þ T cells and of CD34 þ cells, and pretransplantation category were similar in AML or ALL patients with and without KIR ligand mismatch (data not shown).
Although both the high-dose of T cells infused and KIR ligand mismatch were high-risk factors for aGVHD, their roles in relapse differed. The cumulative incidence of relapse tended to be lower in the high-T-cell group compared with the low-T-cell group (8.274.7 vs 27.1716.5%, P ¼ 0.106). KIR ligand mismatch significantly increased the relapse rate of patients regardless of high-or low-T-cell groups (20712.6 vs 4.874.6%, P ¼ 0.025; 36.4721.2 vs 15.678.7%, P ¼ 0.062, respectively), and then resulted in inferior survival in both groups (60715.5 vs 8676.6%, P ¼ 0.045; 26.5715.4 vs 66.378.9%, P ¼ 0.085, respectively). There was no effect of KIR ligand mismatch on TRM in either group.
The results in the present study demonstrated that KIR ligand mismatch is a strong risk factor for aGVHD, relapse and decreased OS, directly contrary to the findings of Perugia's group 1 and the report of Giebel et al. 3 Differences in GVHD prophylaxis and graft cellularity may explain these differences. In Perugia's haploidentical transplant protocol, 1 T-cell depletion is vigorous, with stem cell inoculums containing an average of 3 Â 106 Tcells/kg, compared with an average of 1.5 Â 108 Tcells/kg in our protocol. 4 The other disparity between these two protocols is the use of ATG. Administration of ATG before transplantation results in donor T-cell depletion in vivo. Because ATG persists in the patient circulation for weeks after the allograft, it may also modulate and hamper T-cell reconstitution. Therefore, in the report of Giebel et al. 3 in unrelated HSC transplant with T-cell depletion in vivo by ATG, Effect of KIR ligand mismatch on clinical outcomes. (a or d) Cumulative incidence estimate for the probability of transplantation related mortality (TRM), (b or e) relapse rate and (c or f) Kaplan-Meier estimate for OS for patients with and without KIR ligand mismatch based on pretransplantation risk category, or accordingly based on AML or ALL.
Letters to the Editor KIR ligand mismatch showed beneficial effects on clinical outcomes. In contrast, in the current analysis, the use of ATG failed to demonstrate a beneficial effect of KIR ligand mismatching on transplantation outcome. With a similar dose of ATG (10 mg/kg), our patients received the combination of G-BM and PBSC as allograft, compared with the majority of those patients (125/130) with BM as allograft in Giebel et al.
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The mixture grafts in our protocol contain approximately 10 times more T cells than do BM harvests, 6 which might weaken the in vivo TCD effects of ATG, especially in the high-dose T-cell groups (41.48 Â 10 8 /kg), and the large counts of stem cells infused with G-BM and PBSC might promote T-cell reconstitution. The significant adverse effect of KIR ligand mismatch on the 'high'-T-cell group and the lack of effect on the 'low'-T-cell group in aGVHD also support this hypothesis. Moreover, T cells in the allograft might affect NK cell function and KIR expression in vivo, as reported in unrelated HSCT. 5 Thus, the beneficial roles of NK alloreactivity in transplantation might be inhibited by the large dose of T cells in the allograft in this protocol. The association of the KIR ligand mismatch with a higher incidence of aGVHD might be the result of the alloreactivity of T cells. Likewise, the results in the reports of Farag et al.
2 also suggest any effect of KIR ligand incompatibility may have been marked by the effect of alloreactivity T cells and/ or of posttransplantation immunosuppression.
Our data are striking in that KIR ligand mismatch is an independent risk factor for high aGVHD and relapse rate, which is contrary to the role of a high-dose of T cells in the allograft, which increases aGVHD but decreases relapse. This lack of graft vs leukemia effect despite the development of aGVHD in patients with KIR ligand mismatch may be explained by the poor immune recovery caused by the higher cumulative incidence of aGVHD, which then results in a higher relapse rate. Studies of larger cohorts that include stratification by KIR mismatch status and more detailed infection and complication data are under way and will clarify the role of KIR ligand mismatch on immune recovery and clinical outcomes.
It is important to note that we did not use KIR genotyping to classify our patients but instead relied entirely on HLA typing to determine KIR ligand incompatibility and thus NK cell alloreactivity. However, recent evidence indicates that this assumption may not always be correct, considering KIR and HLA genotypes segregate independently with the expressed KIR repertoire regulated by KIR genotype instead of HLA genotype. Leung et al. 7 reported that KIR-driven NK cell alloreactivity was better predicted if donor KIR genotype was considered along with the HLA type of the recipients in the T-cell-depleted haploidentical transplantation. Meanwhile, the other limitation of the lack of a KIR genotype is the potential confounding effect of activating KIR, which could not be examined in our study but may be important in determining outcomes. Verheyde et al. 8 found that a defined donor activating the NK cell receptor genotype protects against leukemic relapse after related HLAidentical HSCT. Therefore, the underlying mechanisms of these results in the present study are worth further evaluation in a larger prospective study with simultaneous KIR genotyping of donor and recipients.
Although these results were obtained in a limited number of patients with a relatively short follow-up, these findings for haploidentical HSCT without in vitro T-cell depletion show that KIR ligand mismatch is associated with higher aGVHD, a greater relapse rate and inferior survival. Further prospective studies involving larger numbers of patients are necessary to confirm our observations.
